Scientists have developed a novel Omicron-specific mRNA vaccine that offers superior immune protection against two viral subvariants than standard mRNA vaccines. The new vaccine, called Omnivax, increased neutralizing antibody response against the BA.1 and BA.2.12.1 Omicron subvariants in pre-immunized mice 19-fold and eight-fold, respectively, compared with standard mRNA vaccines.